All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
ORLANDO, Fla. – New phase I/II data from Autolus Therapeutics plc announced at the American Society of Hematology’s (ASH) annual conference show that AUTO-3, the first bicistronic CAR T targeting CD19 and CD22 followed by an anti-PD1, was well-tolerated in a phase I/II study.